Sweden · Delayed Price · Currency is SEK Meds Apotek AB Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 18% year-over-year to a record SEK 304 million, with EBIT up 38% and AOV at an all-time high. Gross margin declined to 27.1% due to strategic campaigns, but profitability improved. Guidance is reaffirmed, and the warehouse move is on track for Q3.
-
Q1 2026 delivered above-market growth, strong profitability, and a normalized gross margin, with Rx sales nearly doubling year-over-year. The upcoming move to a larger, more automated logistics center is expected to temporarily impact sales and EBIT but supports long-term growth targets.
Fiscal Year 2025
-
Achieved record sales and profitability, surpassing SEK 1 billion in revenue and 1 million customers, with strong Rx growth and a successful IPO. Gross margin faced Q4 pressure from competition, but cost control and a new warehouse position the company for future expansion.
-
Q3 saw 22% sales growth, 2% EBIT, and strong cash flow, outpacing the market and achieving a milestone 1 million active customers. Prescription drug sales surged 52%, and the company remains on track for 20%-25% annual growth and 3%-5% EBIT margin by 2026.